Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Marc Bonaca to Vascular Surgical Procedures

This is a "connection" page, showing publications Marc Bonaca has written about Vascular Surgical Procedures.

 
Connection Strength
 
 
 
4.287
 
  1. Hsia J, Szarek M, Anand S, Patel MR, Debus S, Berkowitz SD, Muehlhofer E, Haskell LP, Bauersachs RM, Bonaca MP. Rivaroxaban in Patients With Recent Peripheral Artery Revascularization and Renal Impairment: The VOYAGER PAD Trial. J Am Coll Cardiol. 2021 08 17; 78(7):757-759.
    View in: PubMed
    Score: 0.629
  2. Hess CN, Fu JW, Gundrum J, Allen LaPointe NM, Wang TY, Rogers RK, Hiatt WR, Bonaca MP. Diabetes Mellitus and Risk Stratification After Peripheral Artery Revascularization. J Am Coll Cardiol. 2021 06 08; 77(22):2867-2869.
    View in: PubMed
    Score: 0.621
  3. Desai U, Kharat A, Hess CN, Milentijevic D, Lalibert? F, Zuckerman P, Benson J, Lefebvre P, Hiatt WR, Bonaca MP. Incidence of Major Atherothrombotic Vascular Events among Patients with Peripheral Artery Disease after Revascularization. Ann Vasc Surg. 2021 Aug; 75:217-226.
    View in: PubMed
    Score: 0.613
  4. Hess CN, Bonaca MP. Contemporary Review of Antithrombotic Therapy in Peripheral Artery Disease. Circ Cardiovasc Interv. 2020 10; 13(10):e009584.
    View in: PubMed
    Score: 0.593
  5. Bonaca MP, Morrow DA. New clues for optimal diagnosis and treatment of an old foe: the acute aortic syndrome. Eur Heart J Acute Cardiovasc Care. 2020 Oct; 9(3_suppl):S1-S2.
    View in: PubMed
    Score: 0.592
  6. Bonaca MP, Creager MA, Olin J, Scirica BM, Gilchrist IC, Murphy SA, Goodrich EL, Braunwald E, Morrow DA. Peripheral Revascularization in Patients With?Peripheral Artery Disease With?Vorapaxar: Insights From the TRA 2?P-TIMI 50 Trial. JACC Cardiovasc Interv. 2016 10 24; 9(20):2157-2164.
    View in: PubMed
    Score: 0.451
  7. Bonaca MP, Hogan SE. Tradeoffs in Approach to PAD?Revascularization: Shared Decision Making in the Spotlight. J Am Coll Cardiol. 2023 01 31; 81(4):371-373.
    View in: PubMed
    Score: 0.174
  8. Woo K, Siracuse JJ, Klingbeil K, Kraiss LW, Osborne NH, Singh N, Tan TW, Arya S, Banerjee S, Bonaca MP, Brothers T, Conte MS, Dawson DL, Erben Y, Lerner BM, Lin JC, Mills JL, Mittleider D, Nair DG, O'Banion LA, Patterson RB, Scheidt MJ, Simons JP. Society for Vascular Surgery appropriate use criteria for management of intermittent claudication. J Vasc Surg. 2022 07; 76(1):3-22.e1.
    View in: PubMed
    Score: 0.165
  9. Bonaca MP, Hamburg NM, Creager MA. Contemporary Medical Management of Peripheral Artery Disease. Circ Res. 2021 06 11; 128(12):1868-1884.
    View in: PubMed
    Score: 0.155
  10. Bauersachs RM, Szarek M, Brodmann M, Gudz I, Debus ES, Nehler MR, Anand SS, Patel MR, Hess CN, Capell WH, Rogers K, Muehlhofer E, Haskell LP, Berkowitz SD, Hiatt WR, Bonaca MP. Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD?Trial. J Am Coll Cardiol. 2021 07 27; 78(4):317-326.
    View in: PubMed
    Score: 0.154
  11. Qamar A, Morrow DA, Creager MA, Scirica BM, Olin JW, Beckman JA, Murphy SA, Bonaca MP. Effect of vorapaxar on cardiovascular and limb outcomes in patients with peripheral artery disease with and without coronary artery disease: Analysis from the TRA 2?P-TIMI 50 trial. Vasc Med. 2020 04; 25(2):124-132.
    View in: PubMed
    Score: 0.141
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)